Physician profile
Daniel J Arenos
NPI 1285604231
$25,318.95
in general payments reported to CMS, 2019-2025
62 companies · $3,703 in 2025
The $3,703 reported for 2025 was more than what 98% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,240 · 2020: $2,656 · 2021: $4,000 · 2022: $2,982 · 2023: $4,644 · 2024: $5,093 · 2025: $3,703.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $13K · Education: $1.05.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $13,439.44 |
| Education | $1.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,982.45 | 2019-2025 | Qulipta, Vraylar, Ubrelvy |
| Astrazeneca Pharmaceuticals LP | $3,274.91 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Glaxosmithkline, LLC. | $2,094.13 | 2019-2025 | Trelegy Ellipta, Arexvy, Nucala |
| Takeda Pharmaceuticals U.S.A., INC. | $1,286.24 | 2019-2025 | Trintellix, Takhzyro |
| Bausch Health US, LLC | $1,205.31 | 2019-2025 | Aplenzin, Wellbutrin |
| Novo Nordisk INC | $1,145.87 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Axsome Therapeutics, INC. | $1,061.15 | 2023-2025 | Auvelity, Symbravo |
| Lilly USA, LLC | $972.59 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Exact Sciences Corporation | $950.43 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Pfizer INC. | $917.30 | 2019-2025 | |
| Amgen INC. | $694.70 | 2019-2025 | Repatha, Otezla, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $655.55 | 2019-2025 | Jardiance |
| Janssen Pharmaceuticals, INC | $590.82 | 2019-2025 | Spravato |
| Arbor Pharmaceuticals, INC. | $518.75 | 2019-2022 | |
| Allergan, INC. | $500.86 | 2019-2020 |
Show all 62 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Arenos listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.